Form PTO-1449

(Rev. 8-88)

Patent and Trademark Office

ONFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Pena et al.

Filing Date

Sheet 1 of 3

Attorney Docket No.

Filing Date

GrowNo.

U.S. PATENT DOCUMENTS

February 5, 2002

| Examiner | | Patent | | | | | Filing Date |
|------------|----|-----------|--------------|----------------------|-------|----------|----------------|
| Initial | | Number | Issue Date | Name | Class | Subclass | If Appropriate |
| UD | AA | 3,086,912 | Apr 23, 1963 | Bergy et al. | 167 | 65 | |
| | AB | 3,282,780 | Nov 01, 1966 | Martin | 167 | 65 | |
| | AC | 3,300,475 | Jan 24, 1967 | Bannister | 260 | 210 | |
| | AD | 3,313,801 | Apr 11, 1967 | Argoudelis et al. | 260 | 210 | |
| | AE | 3,329,568 | Jul 04, 1967 | Argoudelis et al. | 167 | 65 | |
| | AF | 3,359,164 | Dec 19, 1967 | Argoudelis et al. | 167 | 65 | |
| | AG | 3,361,739 | Jan 02, 1968 | Argoudelis et al. | 260 | 210 | |
| | AH | 3,395,139 | Jul 30, 1968 | Mason et al. | 260 | 210 | |
| | Al | 3,475,407 | Oct 28, 1969 | Birkenmeyer | 260 | 210 | |
| | AJ | 3,487,068 | Dec 30, 1969 | Morozowich et al. | 260 | 210 | |
| | AK | 3,509,127 | Apr 28, 1970 | Kagan <i>et al</i> . | 260 | 210 | |
| | AL | 3,513,155 | May 19, 1970 | Birkenmeyer et al. | 260 | 210 | |
| | AM | 3,544,551 | Dec 01, 1970 | Kagan et al. | 260 | 210 | |
| | AN | 3,580,904 | May 25, 1971 | Morozowich et al. | 260 | 210 | |
| | AO | 3,655,885 | Apr 11, 1972 | Morozowich et al. | 424 | 181 | |
| | AP | 3,676,302 | Jul 11, 1972 | Visser | 195 | 80 | |
| | AQ | 3,705,889 | Dec 12, 1972 | Bannister et al. | 260 | 210 | |
| | AR | 3,714,141 | Jan 30, 1973 | Shephard | 260 | 210 | |
| | AS | 3,726,766 | Apr 10, 1973 | Argoudelis et al. | 195 | 80 | |
| | AT | 3,812,014 | May 21, 1974 | Argoudelis et al. | 195 | 80 | |
| | AU | 3,849,396 | Nov 19, 1974 | Birkenmeyer | 260 | 210 | |
| | AV | 3,969,516 | Jul 13, 1976 | Stoughton | 424 | 181 | |
| | AW | 4,031,304 | Jun 21, 1977 | Bannister | 536 | 11 | |
| | AX | RE 29,558 | Feb 28, 1978 | Bannister | 536 | 11 | |
| | AY | 4,250,169 | Feb 10, 1981 | Hosoi et al. | 424 | 181 | |
| | AZ | 4,271,266 | Jun 02, 1981 | Bergy et al. | 435 | 73 | |
| | ВА | 4,278,789 | Jul 14, 1981 | Birkenmeyer | 536 | 11 | |
| | BB | 4,289,757 | Sep 15, 1981 | Glenn | 424 | 120 | |
| | BC | 4,309,533 | Jan 05, 1982 | Birkenmeyer | 536 | 11 | |
| · | BD | 4,310,660 | Jan 12, 1982 | Birkenmeyer | 536 | 11 | |
| | BE | 4,317,903 | Mar 02, 1982 | Hofstetter | 536 | 11 | |
| | BF | 4,464,466 | Aug 07, 1984 | Argoudelis et al. | 435 | 92 | |
| ah | BG | 4,568,741 | Feb 04, 1986 | Livingston | 536 | 16.5 | |
| VV | ВН | 4,710,565 | Dec 01, 1987 | Livingston et al. | 536 | 16.5 | |
| Evaminar / | 1 | 1 00 | 11' | Data Canaidarad | | | |

Examiner Only Orang H

Date Considered

*Examiner:

TRADE

Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| • | | . : | BEST | T AVAILAB | LE COP | | Š | Skeek | M | |
|--|----------|---------------------------------------|--|------------------------|---|-------|----------|-----------|-----------|---|
| | • | * > | · · · · | | | | | Sheet | 2 018 | |
| Form PTO-1449 U.S. Department f C mm r | | | | | Attorney Docket No. | | | Serta No. | 0 2 | |
| (Rev. 8-88) |) | | Pat int and Tra | ademark Offic | | | | | TEST T | 7 |
| CPE | | | | | 6193/1 10/072/92 | | | | | _ |
| DIFE | NFC | DRMATION DISC | Pat Int and Tra LOSURE STATE eets if necessary | MENT | 6193/1 10/072 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | | | | | |
| • | 3 | (Use several sh | eets if necessary |) | 3 | | | | | |
| EED 0 9 2000 | 1 1 | | | | Pena et al. | | <u> </u> | | | |
| SEP U 3 AM | Ħ | | | | Filing Date | | 9 | aroup No. | | |
| | 3 | | | | Fat 5 0000 | | 1. | let | 5 | |
| PADEL | <u> </u> | | | | February 5, 2002 | | | Inknown | | _ |
| 4333 | | | U | I.S. PATENT DOCL | JMENTS | | | | _ | |
| Examiner | | Patent | | | | | | Filin | g Date | |
| Initial | | Number | Issue Date | Name | | Class | Subcla | | propriate | Э |
| 737 | BI | 4,732,753 | Mar 22, 1988 | Füller | | 424 | 85 | | | |
| , / | BJ | 4,765,978 | Aug 23, 1988 | Abidi <i>et al</i> . | | 424 | 80 | | | |
| | BK | 4,882,359 | Nov 21, 1989 | Nakagawa et al. | | 514 | 947 | | | |
| | BL | 5,436,009 | Jul 25, 1995 | Jauw et al. | | 424 | 436 | | | |
| | ВМ | 6,210,698 | Apr 03, 2001 | Yamazaki <i>et al.</i> | | 424 | 434 | Apr | 06, 2000 |) |
| | BN | 6,255,502 | Jul 03, 2001 | Penkler et al. | | 552 | 549 | Apr | 19, 1999 | |
| | ВО | 6,270,789 | Aug 07, 2001 | Sameshima et al. | | 424 | 433 | Jan | 19, 2000 |) |
| | • | · · · · · · · · · · · · · · · · · · · | FOR | REIGN PATENT DO | CUMENTS | | | | | |
| Examiner | | Document | | | | 1 | | Tra | anslation | |
| Initial* | | Number | Date | Country | | Class | Subcla | ss Yes | No | |
| VIII | BP | 0 206 947 B1 | April 15, 1992 | EPO | | A61K | 31/14 | | | |
| | BQ | WO 87/01935 | Apr 09, 1987 | WIPO | | A61K | 7/48 | | | |
| | BR | WO 88/04938 | Jul 14, 1988 | WIPO | | A61K | 47/00 | | | |
| | BS | WO 88/09130 | Dec 01, 1988 · | WIPO | · | A23K | 1/17 | | | |
| | BT | WO 89/04672 | Jun 01, 1989 ⁻ | WIPO | | A61K | 47/00 | | | |
| | BU | WO 96/34603 | Nov 07, 1996 | WIPO | | A61K | 31/34 | | | |
| l i | BV | WO 96/39838 | Dec 19 1996 | WIPO | | AO1N | 57/00 | | | |

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

WIPO (in German)

A61K

A61K

A61K

A61K

A61K

A61K

A61K

A61K

A61F

31/415

9/14

45/00

31/00

9/02

9/16

9/02

9/14

6/06

X

WO 97/44032

WO 98/14174

WO 98/50074

WO 99/09964

WO 99/29299

WO 01/37808

WO 02/03896

CB WO 00/72827

CC WO 01/10407

BX

BY

BZ

CA

CD

CE

Nov 27, 1997

Apr 09, 1998 -

Nov 12, 1998,

Mar 04, 1999

Jun 17, 1999-

Dec 07, 2000

Feb 15, 2001.

May 31, 2001

Jan 17, 2002

WIPO

WIPO

WIPO

WIPO

WIPO

WIPO

WIPO

WIPO

| BB | CF | Antibiotics, List of Antibacterials Affecting Protein Synthesis, Lincosamides [online]. April 2001. Retrieved from the internet: <url:< th=""></url:<> | | | | |
|----------|----|--|--|--|--|--|
| | | http://www.bmb.leeds.ac.uk/mbiology/ug/ugteach/dental/antibiotics/dantibiobactprotlin.htm >. | | | | |
| Examiner | | Date Considered | | | | |

Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



| . • • | | BEST AVAILABL | E COP | 西哥 | | | |
|-------------|-----------|--|---|----------------------------------|--|--|--|
| | | | + 901 No. | Sheet 8 of 3 | | | |
| Form PTO | 1449 | U.S. Department f Comm rc | Attorney Docket No. | Selection. | | | |
| (Rev. 8-88) | | Patent and Trad mark Offic | | 豆。乙 | | | |
| OF | | | 6193/1 | 10/0727492 | | | |
| 0,,, | _, | RMATION DISCLOSURE STATEMENT | Applicant | S S H | | | |
| | | Use several sheets if necessary) | Done et al | | | | |
| SEP 0 9 | MOUL | <u> </u> | Pena et al. | Croup Al | | | |
| D 251 | | | Filing Date | Group New | | | |
| | Ó | | February 5, 2002 | Unknown | | | |
| SAN JOVE | E | | 1 00.00.7 0, 2000 | , sommette | | | |
| | | OTHER DOCUMENTS (Including author, ti | tle, date, pertinent pages, etc.) | | | | |
| RM | CG | Birkenmeyer et al. Lincomycin, XI, Synthesis and St Med. Chem., 13, pp. 616-619. (1970). | ructure of Clindamycin, a Potent An | tibacterial Agent. J. | | | |
| | СН | Brown et al. Clindamycin Hydrochloride. In K. Florey. Academic Press, pp. 75-91. (1981). | , ed., Analytical Profiles of Drug Sub | ostances, Vol. 10, | | | |
| | CI | Chowhan et al. Suppository Bases (Semi-synthetic | glycerides). In Handbook of Pharma | aceutical Excipients, | | | |
| | | 1 st Ed., American Pharmaceutical Association and | | | | | |
| | | 320. (1986). | • | | | | |
| | 3 | Cleocin Vaginal Ovules. Pharmacia & Upjohn Co (or <url: pharm.asp="" products="" www.pnu.com=""></url:> | nline], September 24, 1999. Retriev | red from the internet: | | | |
| | СК | Coben et al. Suppositories. In Lachman et al., ed.,] | he Theory and Practice of Industria | l Pharmacy, 3 rd Ed., | | | |
| | | Lea & Febiger, pp.564-588. (1986). | | , | | | |
| | CL | Gray et al. The Oral Toxicity of Clindamycin in Labor | atory Animals. Toxicol. Appl. Pharm | acol., 21, pp. 516- | | | |
| | | 531. (1972). | | | | | |
| \ | СМ | Kapusnik-Uner et al. Chapter 47: Antimicrobial Age | | | | | |
| | | Gilman's The Pharmacological Basis of Therapeu | **** | | | | |
| | CN | Leigh. Antibacterial Activity and Pharmacokinetics of A), pp. 3-9. (1981). | Clindamycin. J. Antimicrob. Chemo | other., 7 (Supplement | | | |
| | СО | Lewis. Antiplasmoidal Activity of 7-Halogenated Linc (1968). | omycins. The Journal of Parasitolog | y, 54, pp.169-170. | | | |
| | СР | Lewis. Clinically Useful Antibiotics Obtained by Direct | ted Chemical Modification-Lincomy | rine Federation | | | |
| | | Proceedings, 33 (11), pp. 2303-2306. (1974). | ned Offerfical Modification-Efficienty | cilis. I bubi audii | | | |
| | CQ | Lincomycin, Summary Report 2. Committee for Vete | rinary Medicinal Products. The Furo | pean Agency for the | | | |
| | | Evaluation of Medicinal Products. (July 2000). | , | poditi i igotto y i or alio | | | |
| | CR | Lincosamides. Purdue Research Foundation [online] | , February 20, 1996. Retrieved from | n the internet: | | | |
| | • | <url: bms="" courses<="" depts="" http:="" p="" www.vet.purdue.edu=""></url:> | • | | | | |
| | CS | Macrolides, Lincomycin and Clindamycin. The Merc | k Manual of Diagnosis and Therapy | [online], 2001. | | | |
| | | Retrieved from the internet: | | | | | |
| | | <url: http:="" mmanual="" p="" pubs="" section<="" www.merck.com=""></url:> | | | | | |
| | СТ | Magerlein et al. Chemical Modifications of Lincomyci | n. Antimicrobial Agents and Chemo | otherapy, pp. 727-736. | | | |
| | 011 | (1966). | | 11 1 1 10 | | | |
| | CU | Maurio. A Practical Guide to Antibacterial Agents: M | lacrolide Antibiotics. American Clinic | cal Laboratory, pp. 12- | | | |
| | CV | 13. (April 1997). McGehee et al. Comparative Studies of Antibacterial | Activity In Vitro and Absomtion and | Everation of | | | |
| | | Lincomycin and Clinimycin. Am. J. Med. Sci., 256 | • | Excretion of | | | |
| | CW | McGregor. Bacterial Vaginosis is Associated with Pro | | e and Sialidase | | | |
| | | | | | | | |
| | | Results of a Controlled Trial of Topical Clindamycin Cream. Amercian Journal of Obstetrics and Gynecology, 170, pp. 1048-1060. (April 1994). Retrieved from the internet: | | | | | |
| | | http://gateway2.ovid.com/ovidw-b.cgi. | | | | | |
| 000 | СХ | The Merck Index, 12th Ed., Merck & Co., pp. 397-398 | وبمستقد والمستوال | | | | |
| | CY | Oesterling. Aqueous Stability of Clindamycin. J Phar | m. Sci., 59 (1), pp. 63-67. (January | 1970). | | | |
| Examine |) | Date Considered | | | | | |
| l V | \bigcap | WOULD Pringliff Zlial | 7 2 | | | | |
| *Evamina- | | olif citation accorded to the tital of the control of the citation of the cita | | 21221 | | | |
| *Examiner: | conf | al if citation considered, whether or not citation is in conformation and not considered. Include copy of this form with | ance with MPEP §609; draw line through next communication to applicant. | citation if not in | | | |

DEST AVAILABLE COPY

Mar-25-2004 03:42pm

\$lgnature

PATENT PFIZER ANN ARBOR MI

7346222928

P.008/014 F-042

PTO/68/08A (08-03) Approved for use the ugn 07/31/2008. QMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it our tains a valid OMB control number. Complete if K.10wn Substitute for form 1448/PTO Application Number 10/072,492 Filing Date February 5, 2002 INFORMATION DISCLOSURE First Named Inventor Lorraine E. Pena, et al. STATEMENT BY APPLICANT An Unit 1615 (Use as many shoots as nocossary) Examiner Name Rachel M. Hermen Carlos An Sheet 1 Attorney Docket Number 6193/2/US of 1 U. S. PATENT DOCUMENTS Publication Date Name of Patentae or Examiner Cito **Document Number** Pages, Columns, Lines, Where Inhisis-No. MM-DD-YYYY Relevant Passages or Relevant Applicant of Cited Document Figures Appear Number-Kind Codo² of money ปีร-US. US-US-USus-US-US-

| | | FOREIC | <u>ON PATENT DOCI</u> | UMENTS | | |
|----------------------|------------|---|-----------------------|--|---|----|
| Examiner Inibala* | Cre No. | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columna, Lines, Where Resevant Passages Or Relevant Figures Appear | Tª |
| | | Country Code ² Number ⁴ Kind Code ³ (#known) | MM-DD-YYYY | | | |
| CAL | | GB 1 219 700 | 01/20/1971 | Upjohn Company | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | · | | | |
| | | | <u> </u> | | | |
| Examiner | 17 | | | Data | | |

*EXAMINER: bitial if reference considered, wholper or not citation is in conformance with MPEP 809. Oraw line through d atlan if that in conformance and had considered. Include copy of this form with pext communication to applicant. Applicant's unique citation designation numb of (optional). See Kinds Codes of USPTO Patent Documents at www.usent.gov or MPEP 901.04. Enter office that issued the document, by the two-latter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the pat int document. Kind of document by the appropriate sympole as indicated on the document under WIPO Symidard ST.16 if possible. Applicant is to place a creak mark here if English language Translation is preached.

Considered

This collection of information is required by 37 CFR 1.97 and 1.98 The information is required to optain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, inducing gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be earl to the chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO HIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need pesistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and celect option 2.